GRAL
Grail, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Grail, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report5 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.
No thesis.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−14.53%
vs ±14.1% implied · ×1.03
shaded = implied · ▲▼ = realized
Grail, Inc.
143.46
| Manager | Value | % base | |
|---|---|---|---|
| Farallon | $284.1M | 10.42% | +27.90% |
| Baker Bros. | $275.0M | 10.08% | 0.00% |
| BlackRockindex-like | $244.2M | 8.95% | +20.50% |
| State Streetindex-like | $162.9M | 5.97% | +26.09% |
| Primecap | $148.8M | 5.46% | +18.24% |
| Manager | Value | % base | |
|---|---|---|---|
| Farallon | $284.1M | 10.42% | +27.90% |
| Baker Bros. | $275.0M | 10.08% | 0.00% |
| BlackRockindex-like | $244.2M | 8.95% | +20.50% |
| State Streetindex-like | $162.9M | 5.97% | +26.09% |
| Primecap | $148.8M | 5.46% | +18.24% |
Linked news
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Grail, Inc.'s 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Grail, Inc.'s 6 closest co-movers, 1 shares that code.
Tall tick = annual report · Source: EDGAR
Bull3
Bear1
Expected move
Inputs8Q avg ±15.9%·×0.73·cheap
straddle ±16.9%
spot 143.43exp Nov 20ATM strike 145ATM straddle 28.50IV 103%